Full Press Release Details
Onconova Therapeutics Announces FDA Permission
Proceed Under its Investigational New Drug Application for Multi-
kinase CDK4/6 Inhibitor ON 123300
affirms plans to begin enrollment of patients with HR+ HER2- metastatic breast cancer and other tumors in U.S. Phase 1 trial in
the first half of 2021
Pa., Dec. 21, 2020 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ: ONTX), a biopharmaceutical company focused
on discovering and developing novel products to treat cancer, today announced receipt of U.S. Food and Drug Administration (FDA)
permission for a Phase 1 study to proceed under the Company's Investigational New Drug application (IND) for ON 123300, a
proprietary, differentiated, first-in-class multi-kinase inhibitor.
"We are grateful to receive this
timely, favorable response from the FDA to initiate a Phase 1 trial with ON 123300," said Steven M. Fruchtman, M.D., President
and Chief Executive Officer of Onconova. "We are advancing the process to secure Institutional Review Board approval, and
affirm our expectation that the first patient will be enrolled during the first half of 2021."
The Phase 1 trial will be conducted in
the U.S. and will assess the safety, tolerability and pharmacokinetics of ON 123300 administered orally as monotherapy at increasing
doses starting at 40 mg daily or higher for consecutive 28-day cycles. The trial will enroll patients with relapsed/refractory
advanced cancer, including but not limited to patients with HR+ HER2- metastatic breast cancer with clinical resistance to approved
second-generation CDK4/6 inhibitors. Once the dose escalation phase of the trial is completed and the recommended Phase 2 dose
is established, additional HR+ HER2- postmenopausal metastatic breast cancer patients resistant to approved second-generation CDK4/6
inhibitors will be enrolled. Additional patient cohorts are under consideration, including but not limited to patients diagnosed
with advanced colorectal cancer, and non-Hodgkin's lymphoma, in particular mantle cell lymphoma.
The design of this U.S. Phase 1 trial differs
from the ongoing study with ON 123300 in China conducted by the Company's partner HanX Biopharmaceuticals, Inc., which is
dosing patients daily for 21 days. The HanX trial has enrolled four patients to date, has opened the second dosing cohort and is
expected to continue enrolling patients with advanced cancer at two sites until the recommended Phase 2 dose is identified. Notably,
of the three currently approved CDK4/6 inhibitors, two are approved for dosing in 21-day cycles and one is approved for dosing
in a 28-day cycle. All three are blockbuster drugs marketed in HR+ HER2- metastatic breast cancer by well-known pharmaceutical
companies, and all of these approved therapies require concomitant treatment with an aromatase inhibitor.
"Based on its differentiated mechanism
of action, we believe that ON 123300 presents an innovative approach to study advanced cancers including in HR+ HER2- metastatic
breast cancer that is or has become resistant to commercial CDK4/6 inhibitors. Beyond metastatic breast cancer, we believe that
ON 123300 may present a novel approach to treating other cancers including mantle cell lymphoma, multiple myeloma, advanced colorectal
cancer and hepatocellular carcinoma, as well as inoperable glioblastoma based on preclinical studies suggesting ON 123300 crosses
the blood-brain barrier," added Richard Woodman, M.D, Chief Medical Officer.
Onconova's lead pipeline compound
is the novel small molecule ON 123300, a proprietary, first-in-class multi-kinase inhibitor targeting tumor-driving kinases including
CDK4/6 and ARK5. ON 123300 is reported to simultaneously inhibit both cell cycle and cellular energy metabolism through CDK4/6
and ARK5, respectively, and in vitro has been shown to be cytotoxic to cancer cells (killing the cancer cells). The current
commercial CDK inhibitors are reported to be cytostatic (inhibiting the growth of cancer cells). With its differentiated mechanism
of action, ON 123300 may present an innovative approach for treating solid tumors and hematologic malignancies that are refractory
to or have become resistant to other CDK4/6 inhibitors. Based on experiments in preclinical models, ON 123300 exhibits single-agent
cytotoxicity, and may have utility for certain types of cancers including breast cancer, non-Hodgkin's lymphoma including
mantle cell lymphoma, multiple myeloma, colorectal cancer, hepatocellular carcinoma, and inoperable glioblastoma.
About Onconova Therapeutics, Inc.
Onconova Therapeutics is a biopharmaceutical
company focused on discovering and developing novel products to treat cancer. The Company has proprietary targeted anti-cancer
agents designed to disrupt specific cellular pathways that are important for cancer cell proliferation.
Onconova's novel, proprietary multi-kinase
inhibitor ON 123300 is currently in a dose-escalation and expansion Phase 1 trial in China, and a dose-escalation and expansion
Phase 1 trial is planned in the U.S. to commence in the first half of 2021. Onconova's product candidate oral rigosertib
is currently in a dose-escalation and expansion Phase 1 investigator-initiated study targeting patients with KRAS+ lung adenocarcinoma
in combination with nivolumab. Preclinical work with rigosertib in COVID-19 is ongoing as well. Although some preclinical experiments
with rigosertib in cellular models demonstrated marked inhibition of SARS-CoV-2 replication, we do not anticipate conducting clinical
trials with rigosertib in COVID-19 without securing additional funding. For more information, please visit www.onconova.com.
Forward-Looking Statements
Some of the statements in this release
are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, Section 21E of the
Securities Exchange Act of 1934, as amended, and the Private Securities Litigation Reform Act of 1995, and involve risks and uncertainties.
These statements relate to Onconova's expectations regarding its patents and clinical development plans including patient
enrollment timelines and indications for its product candidates. Onconova has attempted to identify forward-looking statements
by terminology including "believes," "estimates," "anticipates," "expects," "plans,"
"intends," "may," "could," "might," "will," "should," "approximately"
or other words that convey uncertainty of future events or outcomes. Although Onconova believes that the expectations reflected
in such forward-looking statements are reasonable as of the date made, expectations may prove to have been materially different
from the results expressed or implied by such forward-looking statements. These statements are only predictions and involve known
and unknown risks, uncertainties, and other factors, including the success and timing of Onconova's clinical trials and regulatory
agency and institutional review board approvals of protocols, Onconova's ability to continue as a going concern, the need
for additional financing, Onconova's collaborations, and those discussed under the heading "Risk Factors" in Onconova's
most recent Annual Report on Form 10-K and quarterly reports on Form 10-Q. Any forward-looking statements contained in this release
speak only as of its date. Onconova undertakes no obligation to update any forward-looking statements contained in this release
to reflect events or circumstances occurring after its date or to reflect the occurrence of unanticipated events.
LHA Investor Relations